Instil Bio, Inc. (TIL)

NASDAQ: TIL · Real-Time Price · USD

22.26

-1.75 (-7.29%)

Jan 31, 2025, 4:00 PM EST - Market closed

Instil Bio Employees

Instil Bio had 49 employees as of December 31, 2023. The number of employees decreased by 143 or -74.48% compared to the previous year.

Employees

49

Change (1Y)

-143

Growth (1Y)

-74.48%

Revenue / Employee

n/a

Profits / Employee

-$1,533,980

Market Cap

145.27M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	49	-143	-74.48%
Dec 31, 2022	192	-220	-53.40%
Dec 31, 2021	412	262	174.67%
Dec 31, 2020	150	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	122,000
Abbott Laboratories	114,000
AstraZeneca	89,900
Novartis AG	76,057
Merck & Co.	72,000
Novo Nordisk	64,319

Employee Rankings

TIL News

18 days ago - Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - GlobeNewsWire
24 days ago - Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
2 months ago - Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity - Seeking Alpha
4 months ago - Crude Oil Surges Over 1%; Instil Bio Shares Plunge - Benzinga
4 months ago - Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - GlobeNewsWire
5 months ago - Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements - Seeking Alpha
6 months ago - Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
6 months ago - Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody - GlobeNewsWire